Tessera
Folgen

Mike Hubank

@generoom.bsky.social

Clinical Genomics in the UK. Scientific Director of Clinical Genomics at the Royal Marsden and North Thames GLH. Prof of Translational Genomics at ICR, London

224 Posts593 Follower467 Folgt
Maria Secrier@mariasecrier.bsky.social · 4w ago

Interested in using AI, computational genomics and single-cell/spatial omics to tackle breast cancer dormancy and late recurrence? Join our team and work in collaboration with @magnanilab.bsky.social at ICR on an exciting interdisciplinary postdoc project: www.ucl.ac.uk/work-at-ucl/...

UCL – University College London

UCL is consistently ranked as one of the top ten universities in the world (QS World University Rankings 2010-2022) and is No.2 in the UK for research power (Research Excellence Framework 2021).

ucl.ac.uk

KaminskiMed@kaminskimed.bsky.social · 2mo ago

Finally!! The World Medical Association send letter to Israel's Prime Minister, about Dr. Abu Safiya demanding immediate access to independent medical care, evaluation for torture; due process or release; end to solitary confinement #SaveDrAbuSafiya www.wma.net/news-post/wm...

WMA - The World Medical Association-WMA renews urgent appeal to Israeli authorities over detained Gaza physicians, citing “grave concerns” for Dr Abu Safiya’s life

WMA - The World Medical Association

wma.net

Jon Lim, FRCP PhD@drjonlim.bsky.social · 3mo ago

Almost 2️⃣ years in… Our MANIFEST AGM convened scientists, clinicians, patient partners & industry. Keynotes from Prof Levesque & Prof Rattray + Prof Turajlić setting the course ahead. Big thank you to all for continuing to believe in the vision; to tackle the hard questions in #CancerImmunotherapy.

BildBildBildBild
Eric Topol@erictopol.bsky.social · 3mo ago

Big progress vs cancer, folks. The kind of event curves from randomized trials that we've not seen before for a couple of the most deadly cancers. Congrats to the oncology research community for getting these trial done.

Bild
Becki Lee@beckilee.bsky.social · 3mo ago

Pleased to share results from the CAcTUS Phase II trial of ctDNA-guided therapy in BRAF-mutant advanced melanoma are now published! 🌵🧬 CAcTUS is the first melanoma trial to adapt treatment based on ctDNA testing. Read: www.nature.com/articles/s41...

Use of circulating tumour DNA to prospectively guide a switch from targeted to immune therapy in BRAF mutant advanced melanoma: the randomised phase II CAcTUS trial - Nature Communications

Targeted therapy (with BRAK and MEK inhibitors) and immune checkpoint blockade have improved survival for patients with advanced BRAF-mutant cutaneous melanoma, however, the optimal scheduling for the...

nature.com

Mark Peifer (He, him)@peiferlabunc.bsky.social · 4mo ago

While BioNtech & Moderna become household names because of their Covid vaccines, those emerged from different projects: finding ways to treat the most challenging cancers. They hypothesized that we could vaccinate patients against their own tumors, & evidence is mounting that they were right! 1/n 🧪

https://www.nature.com/articles/s41586-025-10004-2 Individualized mRNA vaccines evoke durable T cell immunity in adjuvant TNBC U. Sahin, M. Schmidt, E. Derhovanessian, A. Cortini, I. Vogler, T. Omokoko, E. Godehardt, S. Attig, S. Newrzela, J. Grützner, N. Bidmon, S. Bolte, S. Brachtendorf, T. Stuhlmann, D. Langer, D. Brüne, J. Blake, A. Feldner, H. Lindman, A. Schneeweiss, M. Eichbaum & Ö. Türeci Triple-negative breast cancer (TNBC) is frequently associated with metastatic relapse, even at an early stage1. Here we assessed an individualized neoantigen mRNA vaccine in 14 patients with TNBC following surgery and after neoadjuvant or adjuvant therapy. In peripheral blood of nearly all patients, high-magnitude, vaccine-induced, mostly de novo T cell responses to multiple neoantigens were detected that remained functional for several years. Characterization of individual patients revealed that a large proportion of these T cells developed into two subsets: a late-differentiated phenotype with markers indicative of ‘ready-to-act’ cytotoxic effector T cells, and T cells with a stem cell-like memory phenotype. Eleven patients remained relapse-free for up to six years post-vaccination. Recurrence occurred in three patients: the individual with the weakest vaccine-induced T cell response relapsed, but achieved complete remission on subsequent anti-PD-1 therapy; another patient had a tumour with low major histocompatibility complex (MHC) class I expression with MHC class I-deficient cells growing out under vaccination; and the third patient was BRCA-positive and had a recurrence from a genetically distinct primary tumour. These findings demonstrate the feasibility of individualized RNA vaccines in TNBC, document persistence of vaccine-induced, functional neoantigen-specific T cells and provide insights into possible immune escape mechanisms that will guide future approaches.
Chris Lord and Andrew Tutt’s Lab Institute of Cancer Research@icrlordlab.bsky.social · 4mo ago

If you are interested in PARP inhibitors and history, this might be of interest to you. www.nature.com/articles/s41.... An attempt to cover the work of thousands and their immense contributions to the development of a targeted approach to treating cancers.

Two decades of PARP inhibitor synthetic lethality in cancer - Nature

The past two decades of PARP inhibitor synthetic lethality in cancer is explored.

nature.com

Prof Christina Pagel@chrischirp.bsky.social · 4mo ago

NHS data should be driving innovation & improvement – it’s an amazing resource We just published the sequel to our 2021 "Road to Hell" paper on using NHS data for research... things are worse! Buckle up for a long 🧵about *how COMPLETELY mad* system is for accessing NHS data for research 1/20

Bild
Chris Wallace@chr1sw.bsky.social · 4mo ago

Very important thread about accessing NHS data for scientific progress. We (our processes, not our researchers) need to get better at this.

Prof Christina Pagel@chrischirp.bsky.social · 4mo ago

NHS data should be driving innovation & improvement – it’s an amazing resource We just published the sequel to our 2021 "Road to Hell" paper on using NHS data for research... things are worse! Buckle up for a long 🧵about *how COMPLETELY mad* system is for accessing NHS data for research 1/20